Diffuse large B Cell lymphoma: How can we cure more patients in 2012?

Craig Moskowitz

doi:10.1016/j.beha.2012.01.008

Back

Diffuse large B Cell lymphoma: How can we cure more patients in 2012?

Journal article

Peer reviewed

Diffuse large B Cell lymphoma: How can we cure more patients in 2012?

Craig Moskowitz

Best practice & research. Clinical haematology, Vol.25(1), pp.41-47

2012-03

DOI: https://doi.org/10.1016/j.beha.2012.01.008

PMID: 22409822

Abstract

cell or origin

diffuse large B cell lymphoma

double hit lymphoma

FDG-PET

Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.

Metrics

3 Record Views

11 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.132 Lymphoma
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Diffuse large B Cell lymphoma: How can we cure more patients in 2012?
Creators: Craig Moskowitz - Division of Hematologic Oncology, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, United States
Publication Details: Best practice & research. Clinical haematology, Vol.25(1), pp.41-47
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Department of Medicine
Language: English
Resource Type: Journal article
PMID: 22409822
Record Identifier: 991031613880502976